Fresh turmoil inside Novartis’ revamped CAR-T organization as top exec jumps ship
There’s more turmoil to report from inside Novartis’ CAR-T camp.
On Friday Karen Walker will leave a senior position in charge of CMC/manufacturing of CAR-Ts for Novartis in exchange for a new position she’s taking at Seattle Genetics, Endpoints News has learned.
Walker — the VP Global Head Cell and Gene Therapies Technical Development and Manufacturing at Novartis — was one of three senior execs put in charge of the cell and gene therapy initiative at the company last fall, according to sources close to the company, after a bruising restructuring over the summer in which the unit was chopped up and absorbed inside a huge R&D organization. Samuele Butera was put in charge of the commercial/business aspect of the group while David Lebwohl handles clinical ops.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.